Published in J Inflamm (Lond) on November 20, 2013
Hypoxia-dependent regulation of inflammatory pathways in immune cells. J Clin Invest (2016) 0.86
Therapeutic inhibition of prolyl hydroxylase domain-containing enzymes in surgery: putative applications and challenges. Hypoxia (Auckl) (2015) 0.76
Hypoxia Inducible Factor (HIF) Hydroxylases as Regulators of Intestinal Epithelial Barrier Function. Cell Mol Gastroenterol Hepatol (2017) 0.75
Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol (2017) 0.75
Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A (2006) 4.08
Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell (2004) 3.77
Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology (2008) 2.99
The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology (2007) 2.87
Hypoxia and gastrointestinal disease. J Mol Med (Berl) (2007) 2.06
Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. Am J Pathol (1994) 2.04
Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol (1999) 1.91
Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology (2010) 1.64
The anti-death machinery in IKK/NF-kappaB signaling. J Clin Immunol (2005) 1.27
Hydroxylase inhibition abrogates TNF-alpha-induced intestinal epithelial damage by hypoxia-inducible factor-1-dependent repression of FADD. J Immunol (2010) 1.05
Targeting hypoxia-inducible factor-1 (HIF-1) signaling in therapeutics: implications for the treatment of inflammatory bowel disease. Recent Pat Inflamm Allergy Drug Discov (2009) 0.94
Hydroxylases as therapeutic targets in inflammatory bowel disease. Lab Invest (2013) 0.92
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet (2007) 8.63
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet (2010) 3.22
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology (2009) 2.26
Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst (2009) 2.09
Clinical impact of capsule endoscopy on further strategy and long-term clinical outcome in patients with obscure bleeding. Gastrointest Endosc (2008) 1.72
Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology (2011) 1.65
Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology (2002) 1.55
Faecal leukocyte esterase activity is an alternative biomarker in inflammatory bowel disease. Clin Chem Lab Med (2015) 1.41
Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis (2009) 1.39
Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol (2002) 1.34
EGFR in melanoma: clinical significance and potential therapeutic target. J Cutan Pathol (2011) 1.32
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol (2002) 1.32
Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. J Med Microbiol (2009) 1.24
The paradox of the unfolded protein response in cancer. Anticancer Res (2013) 1.21
NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology (2002) 1.20
Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis (2012) 1.18
Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep (2002) 1.06
Hydroxylase inhibition abrogates TNF-alpha-induced intestinal epithelial damage by hypoxia-inducible factor-1-dependent repression of FADD. J Immunol (2010) 1.05
Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation. Int J Exp Pathol (2008) 1.02
Decreased colonization of fecal Clostridium coccoides/Eubacterium rectale species from ulcerative colitis patients in an in vitro dynamic gut model with mucin environment. FEMS Microbiol Ecol (2011) 0.98
Extrapancreatic inflammation on abdominal computed tomography as an early predictor of disease severity in acute pancreatitis: evaluation of a new scoring system. Pancreas (2007) 0.97
Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis (2013) 0.94
Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis (2007) 0.93
An intravital microscopic study of the hepatic microcirculation in cirrhotic mice models: relationship between fibrosis and angiogenesis. Int J Exp Pathol (2008) 0.93
Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study. Liver Int (2006) 0.93
Involvement of endoplasmic reticulum stress in inflammatory bowel disease: a different implication for colonic and ileal disease? PLoS One (2011) 0.92
Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol (2010) 0.91
Human metallothionein expression under normal and pathological conditions: mechanisms of gene regulation based on in silico promoter analysis. Crit Rev Eukaryot Gene Expr (2009) 0.91
Evidence for significant overlap between common risk variants for Crohn's disease and ankylosing spondylitis. PLoS One (2010) 0.91
Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Acta Gastroenterol Belg (2008) 0.89
Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. Cancer Invest (2008) 0.89
C-ANCA/proteinase 3-positive colitis in children: a distinctive form of inflammatory bowel disease or vasculitis with colitis as initial presentation? J Pediatr Gastroenterol Nutr (2013) 0.88
Evidence for a potential role of metallothioneins in inflammatory bowel diseases. Mediators Inflamm (2009) 0.88
Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease. BMC Immunol (2010) 0.87
Absence of placental growth factor blocks dextran sodium sulfate-induced colonic mucosal angiogenesis, increases mucosal hypoxia and aggravates acute colonic injury. Lab Invest (2010) 0.86
Cigarette smoking alters epithelial apoptosis and immune composition in murine GALT. Lab Invest (2011) 0.85
Role of placental growth factor in mesenteric neoangiogenesis in a mouse model of portal hypertension. Gastroenterology (2009) 0.85
Inverse correlation between metallothioneins and hypoxia-inducible factor 1 alpha in colonocytes and experimental colitis. Biochem Biophys Res Commun (2011) 0.84
Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study. Acta Gastroenterol Belg (2007) 0.84
Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion. Nephrol Dial Transplant (2011) 0.83
Prognostic value of tumor shrinkage versus fragmentation following radiochemotherapy and surgery for rectal cancer. Virchows Arch (2015) 0.83
A dried yeast fermentate selectively modulates both the luminal and mucosal gut microbiota and protects against inflammation, as studied in an integrated in vitro approach. J Agric Food Chem (2013) 0.83
Rapamycin prevents mesenteric neo-angiogenesis and reduces splanchnic blood flow in portal hypertensive mice. Hepatol Res (2008) 0.83
Effects of vagus nerve stimulation on pro- and anti-inflammatory cytokine induction in patients with refractory epilepsy. J Neuroimmunol (2009) 0.83
Metallothionein and stress combine to affect multiple organ systems. Cell Stress Chaperones (2014) 0.83
Clinical and genetic factors associated with sacroiliitis in Crohn's disease. J Gastroenterol Hepatol (2007) 0.82
Endoplasmic reticulum stress and angiogenesis: is there an interaction between them? Liver Int (2014) 0.82
Immunogenicity of infliximab: how to handle the problem? Acta Gastroenterol Belg (2007) 0.82
Expression of galectins-1, -3 and -4 varies with strain and type of experimental colitis in mice. Int J Exp Pathol (2008) 0.82
Human mast cells express leptin and leptin receptors. Histochem Cell Biol (2009) 0.82
In vitro evaluation of motilin agonism by macrolide immunosuppressive drugs. Nephrol Dial Transplant (2002) 0.81
The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenet Genomics (2006) 0.81
No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. Pharmacogenet Genomics (2006) 0.81
Nuclear expression of STAT6 in dedifferentiated liposarcomas with a solitary fibrous tumor-like morphology: a diagnostic pitfall. Appl Immunohistochem Mol Morphol (2015) 0.81
Outcome of acute nonvariceal gastrointestinal haemorrhage after nontherapeutic arteriography compared with embolization. Eur Radiol (2003) 0.81
The intimate relationship between gut and joint in spondyloarthropathies. Curr Opin Rheumatol (2007) 0.81
Intestinal metaplasia and colonization of endometriosis in a case of an appendiceal mucinous neoplasm. Virchows Arch (2012) 0.81
Invariant natural killer T cells are natural regulators of murine spondylarthritis. Arthritis Rheum (2010) 0.80
Cholestasis as presenting symptom of portal cavernoma. Hepatol Res (2003) 0.80
Measurement of porto-systemic shunting in mice by novel three-dimensional micro-single photon emission computed tomography imaging enabling longitudinal follow-up. Liver Int (2010) 0.80
Role of metallothioneins as danger signals in the pathogenesis of colitis. J Pathol (2014) 0.80
Influence of somatostatin and octreotide on liver microcirculation in an experimental mouse model of cirrhosis studied by intravital fluorescence microscopy. Liver Int (2008) 0.80
Atypical spindle cell lipoma: a clinicopathologic, immunohistochemical, and molecular study emphasizing its relationship to classical spindle cell lipoma. Virchows Arch (2014) 0.80
Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice. Inflamm Bowel Dis (2008) 0.79
Hepatitis mouse models: from acute-to-chronic autoimmune hepatitis. Int J Exp Pathol (2014) 0.79
Pharmacologic activation of tumor hypoxia: a means to increase tumor 2-deoxy-2-[18F]fluoro-D-glucose uptake? Mol Imaging (2013) 0.78
Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent. Eur J Gastroenterol Hepatol (2014) 0.78
Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study. Pharmacogenet Genomics (2006) 0.78
Boosting the hypoxia-induced adaptive response in inflammatory bowel disease: a novel concept of treatment. Inflamm Bowel Dis (2010) 0.78
Genome-Wide Copy Number Variation Scan Identifies Complement Component C4 as Novel Susceptibility Gene for Crohn's Disease. Inflamm Bowel Dis (2016) 0.78
MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option? Virchows Arch (2010) 0.78
Array-based comparative genomic hybridization analysis of a pleomorphic myxoid liposarcoma. J Clin Pathol (2014) 0.78
The role of aminosalicylates in the treatment of ulcerative colitis. Acta Gastroenterol Belg (2003) 0.77
Decreased leukocyte recruitment in the mesenteric microcirculation of rats with cirrhosis is partially restored by treatment with peginterferon: an in vivo study. J Hepatol (2006) 0.77
Intrarectal nitric oxide administration prevents cellular infiltration but not colonic injury during dextran sodium sulfate colitis. Dig Dis Sci (2012) 0.77